Pyxis Oncology (PYXS) Net Equity Issued and Repurchased (2021)
Pyxis Oncology (PYXS) posted quarterly Net Equity Issued and Repurchased of -$19000.0 for Q2 2021, down 100.01% quarter-over-quarter from $151.6 million in Q1 2021.
Pyxis Oncology (PYXS) Net Equity Issued and Repurchased (2021) Analysis & Trends
Pyxis Oncology (PYXS) has reported Net Equity Issued and Repurchased for 1 consecutive years, with -$19000.0 the latest figure, recorded in Q2 2021.
- In Q2 2021, Net Equity Issued and Repurchased changed N/A year-over-year to -$19000.0; the TTM figure through Dec 2021 stood at $151.6 million (changed N/A YoY), while the FY2021 annual figure was $151.6 million, up 5052600.0% from the prior year.
- Net Equity Issued and Repurchased eased to -$19000.0 in Q2 2021 per PYXS's latest filing, from $151.6 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $151.6 million in Q1 2021 and bottomed at -$19000.0 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Pyxis Oncology | 198.37 Mn | 165.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -19,000.00 |
| Jun 30, 2021 | -19,000.00 |
| Mar 31, 2021 | 151.60 Mn |
| Mar 31, 2021 | 151.60 Mn |